FIELD: biotechnology.
SUBSTANCE: described is the use of an expression vector based on an adeno-associated virus containing a codon-optimized sequence of the AIPL1 gene SEQ ID NO: 2, to reduce the intracellular immune response when introduced into human retinal cells.
EFFECT: reduced expression of pro-inflammatory genes (IL6, IL1RAPL) and increased expression of anti-inflammatory genes (IL1RN), with stable expression of the hAIPL1 gene introduced into human retinal cells using an AAV-based viral expression vector.
2 cl, 9 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CODON-OPTIMISED HAIPL1-ENCODING NUCLEOTIDE SEQUENCE AND EXPRESSION VECTOR CONTAINING SAID SEQUENCE | 2021 |
|
RU2785621C1 |
| MINI-PROTEIN USH2A, NUCLEIC ACID CODING MINI-PROTEIN USH2A, AND EXPRESSION VECTOR FOR GENE THERAPY CONTAINING SAME | 2023 |
|
RU2822884C1 |
| MITOCHONDRIAL LOCALIZATION PEPTIDE, NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE CONTAINING ITS EXPRESSION VECTOR AND ITS USE | 2023 |
|
RU2817420C1 |
| NUCLEIC ACID FOR ALLOTOPIC EXPRESSION OF MT-ND4 GENE | 2023 |
|
RU2809065C1 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| VECTORS AND SEQUENCES FOR TREATING DISEASES | 2011 |
|
RU2588667C2 |
| METHOD OF TREATING LAMELLAR ICHTHYOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS BASED ON A GENETIC CONSTRUCT CODING A NUCLEOTIDE SEQUENCE OF A TRANSGLUTAMINASE 1 GENE | 2023 |
|
RU2821567C1 |
| NUCLEIC ACID DESIGNED TO REDUCE MAMMALIAN BODY WEIGHT, EXPRESSION VECTOR FOR EXPRESSION IN MAMMALIAN CELLS, METHOD FOR ITS DELIVERY AND METHOD FOR REDUCING MAMMALIAN BODY WEIGHT | 2023 |
|
RU2810191C1 |
| DRUG FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY AND A METHOD FOR ITS TREATMENT | 2021 |
|
RU2769577C1 |
| RECOMBINANT ADEN-ASSOCIATED VIRUS, WHICH IS HYBRID OF AAV9 AND AAVrh74 SEROTYPES, WITH REDUCED TROPISM FOR LIVER TISSUE | 2019 |
|
RU2812279C2 |
